Breast Cancer: Our Clinical Trials

You may be offered the opportunity to take part in a clinical trial at some point during your treatment. Clinical trials are research studies that evaluate the safety and effectiveness of new treatment approaches for diseases. In some cases, a study may give you access to new therapies that are not yet readily available. Clinical trials may also be used to compare diagnostic tests, prevention strategies, or other aspects of care for cancer patients. Learn more about clinical trials.

Below is a listing of breast cancer clinical trials that are currently enrolling patients at Memorial Sloan Kettering Cancer Center.

Showing 1 - 50 of 56 trials
Title Investigatorsort icon
Cognition in Older Breast Cancer Survivors: Influence of Treatment, Genetics, and Smoking History
[Protocol 14-071]
Ahles, Tim, PhD
Risk for Cognitive Decline in Older Women with Breast Cancer
[Protocol 10-079]
Ahles, Tim, PhD
A Phase I Study of BKM120 and Olaparib in Patients with High-Grade Serous Ovarian Cancer
[Protocol 12-233]
Bell-McGuinn, Katherine, MD, PhD
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
[Protocol 10-071]
Blinder, Victoria, MD
A Phase I/II Study of Nivolumab Alone and with Ipilimumab in Patients with Advanced or Metastatic Solid Tumors
[Protocol 13-187]
Callahan, Margaret, MD, PhD
A Study of Non-Hormonal Vaginal Moisturizer in Hormone Receptor-Positive Postmenopausal Cancer Survivors
[Protocol 12-232]
Carter, Jeanne, PhD
Acupuncture for Chronic Lymphedema After Breast Cancer Treatment
[Protocol 12-210]
Cassileth, Barrie, PhD
Molecular Mechanisms of Clinical Resistance to Anti-HER2 Therapy Among Patients with HER2-Amplified Breast Cancer
[Protocol 06-163]
Chandarlapaty, Sarat, MD, PhD
A Phase I/II Clinical Trial of Temsirolimus plus Neratinib for Subjects with Metastatic HER2-Amplified or Triple-Negative Breast Cancer
[Protocol 10-005]
Chandarlapaty, Sarat, MD, PhD
A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer
[Protocol 10-142]
Dang, Chau, MD
A Phase III Study of BKM120 with Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
[Protocol 12-290]
Dickler, Maura, MD
A Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
[Protocol 13-049]
Dickler, Maura, MD
A Phase I Study of BYL719 with Letrozole or Exemestane for Treating Locally Advanced Inoperable or Metastatic Breast Cancer
[Protocol 13-027]
Dickler, Maura, MD
A Phase II Study of Paclitaxel plus Tivozanib or Placebo in Women with Persistent or Recurrent Triple-Negative Breast Cancer
[Protocol 13-047]
Dickler, Maura, MD
Two Studies of GDC-0032: A Phase I Study of GDC-0032 for Solid Tumors with Increased PI3K Activity, and a Phase II Study of GDC-0032 with Fulvestrant in Patients with Advanced Breast Cancer
[Protocol 13-149]
Dickler, Maura, MD
A Phase II Study of Fulvestrant Alone or with GDC-0941 or GDC-0980 in Women with Advanced Breast Cancer Resistant to Aromatase Inhibitor Therapy
[Protocol 12-029]
Dickler, Maura, MD
A Phase I Study of Lurbinectedin plus Paclitaxel in Patients with Advanced Solid Tumors
[Protocol 13-170]
Drilon, Alexander, MD
A Phase II Study of Cabozantinib in Women with Hormone Receptor-Positive Breast Cancer that Spread to the Bone
[Protocol 12-091]
Fornier, Monica, MD
A Phase I-II Study of Dasatinib plus Paclitaxel in Patients with Metastatic Breast Cancer
[Protocol 08-122]
Fornier, Monica, MD
A Phase Ib Study of Oral BGJ398 and BYL719 in Patients with Certain Advanced Solid Tumors
[Protocol 13-246]
Fury, Matthew, MD, PhD
A Phase I Study of HER2/neu DNA Immunization for Patients with Metastatic or High-Risk Breast Cancer
[Protocol 04-101]
Gilewski, Teresa, MD
A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
[Protocol 12-249]
Goldfarb, Shari, MD
A Phase II Study of Multi-Beam Intensity-Modulated Radiation Therapy for Patients with Locally Advanced Breast Cancer Who Had Implant Reconstruction
[Protocol 14-028]
Ho, Alice, MD
A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
[Protocol 12-267]
Hudis, Clifford, MD
A Phase III Study of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
[Protocol 11-190]
King, Tari, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Phase I Study of Topical Calcitriol (Compound 31543) to Prevent Hair Loss in Women Receiving Paclitaxel for Advanced Breast Cancer
[Protocol 11-205]
Lacouture, Mario, MD
A Phase III Study of Hormone Therapy with and without Chemotherapy in Patients with HER2-Negative Breast Cancer and 1-3 Positive Lymph Nodes and a Recurrence Score of 25 or Less
[Protocol 12-118]
Lake, Diana, MD
Quality of Life Assessment in Breast Cancer Patients with Radiation-Induced Telangiectasias Treated with Pulsed Dye Laser
[Protocol 13-013]
Lee, Erica, MD
Assessment of a Customized Computer Program for Reducing Fears of Breast Cancer Recurrence
[Protocol 11-204]
Lichtenthal, Wendy, PhD
Development of Group Interventions for Breast Cancer Survivors
[Protocol 12-291]
Lichtenthal, Wendy, PhD
A Phase IB Study of LEE011 and Exemestane with and without Everolimus in Women with Locally Advanced or Metastatic Breast Cancer
[Protocol 13-179]
Modi, Shanu, MD
A Phase I Study of Ganetespib with Paclitaxel and Trastuzumab in Women with Metastatic Breast Cancer
[Protocol 13-168]
Modi, Shanu, MD
EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
[Protocol 10-104]
Oeffinger, Kevin, MD
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051]
Offit, Kenneth, MD
A Phase III Study Comparing Mometasone Furoate with Eucerin to Treat Radiation-Related Skin Redness and Peeling in Breast Cancer Patients after Mastectomy
[Protocol 13-069]
Olm-Shipman, Molly, RN
A Study Assessing Varenicline (Chantix) to Treat Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy and Reconstructive Surgery
[Protocol 11-136]
Ostroff, Jamie, PhD
A Phase III Study of Accelerated Whole Breast Radiation Therapy with a Boost versus Standard Whole Breast Radiation with a Boost in Women with Early-Stage Breast Cancer (RTOG 1005)
[Protocol 12-158]
Parhar, Preeti, MD
A Phase I/II Study of Intrathecal Trastuzumab in Women with HER2-Positive Breast Cancer that Spread to the Spinal Fluid
[Protocol 12-123]
Pentsova, Elena, MD
Quality of Life and Patient-Reported Outcomes After Breast Reconstruction Surgery
[Protocol 12-093]
Pusic, Andrea, MD, MHS
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea, MD, MHS
Understanding Decision-Making Processes for Undergoing Genetic Testing Among Women with Newly Diagnosed Breast Cancer
[Protocol 11-086]
Robson, Mark, MD
A Phase II Study of Veliparib plus Temozolomide, Veliparib plus Carboplatin and Paclitaxel, or Carboplatin and Paclitaxel with Placebo in Patients with BRCA Mutations and Metastatic Breast Cancer
[Protocol 12-122]
Robson, Mark, MD
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116]
Roth, Andrew, MD
A Phase I Study of GL-ONC1 for Treating Malignant Pleural Effusion
[Protocol 12-169]
Rusch, Valerie, MD
A Phase I Study of Whole Brain Radiation Therapy plus Sorafenib for Patients with Breast Cancer Brain Metastases
[Protocol 12-046]
Seidman, Andrew, MD
Evaluating the Causes of Cancer in Young Patients
[Protocol 09-068]
Stadler, Zsofia, MD
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
[Protocol 12-089]
Tew, William, MD
A Phase II Study of Weekly Paclitaxel with and without LCL161 in Women with Previously Untreated Triple-Negative Breast Cancer
[Protocol 13-082]
Traina, Tiffany, MD
A Phase II Study of Exemestane with and without Enzalutamide in Women with Advanced Hormone Receptor-Positive Breast Cancer
[Protocol 13-257]
Traina, Tiffany, MD